Actively Recruiting
Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients
Led by Xijing Hospital · Updated on 2024-04-19
3000
Participants Needed
1
Research Sites
530 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this prospective multi-center, observational registry in China is to collect clinical baseline, procedural, and follow-up data of all patients treated with TAVR in China and to evaluate short-, mid-, and long-term clinical outcome data of all post-marketing transcatheter valves. Each center will collect baseline and procedural data as well as clinical outcomes for up to 10 years.
CONDITIONS
Official Title
Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with aortic valve disease evaluated by a cardiac team and recommended for TAVR therapy
- Patients who understand the study purpose, agree to participate voluntarily, and sign informed consent
You will not qualify if you...
- Patients with aortic valve disease evaluated by a cardiac team as unsuitable for TAVR
- Patients who cannot tolerate materials or medications used in this study
- Women who are pregnant or breastfeeding
- Patients who participated in another drug or medical device clinical trial before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ling Tao
Xi'an, Shaanxi, China, 710032
Actively Recruiting
Research Team
R
Rutao Wang, M.D, Ph.D
CONTACT
R
Ruining Zhang, BSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here